Dosing Sacubitril/Valsartan in HFrEF with CKD Stage 3a (eGFR 45)
Start sacubitril/valsartan at the standard dose of 49/51 mg twice daily in this patient with eGFR 45 mL/min/1.73 m²—no dose reduction is needed for CKD stage 3a. 1
Starting Dose Selection
Your patient with eGFR 45 has moderate renal impairment (CKD stage 3a), not severe renal impairment. The FDA label explicitly states that dose reduction to 24/26 mg twice daily is only required when eGFR is less than 30 mL/min/1.73 m² (severe renal impairment). 1 For mild or moderate renal impairment, no starting dose adjustment is needed. 1
Key Dosing Algorithm:
- If eGFR ≥30: Start at 49/51 mg twice daily (standard dose)
- If eGFR <30: Start at 24/26 mg twice daily (half dose)
- Your patient (eGFR 45): Use 49/51 mg twice daily
Important Pre-Initiation Considerations
Before starting, verify the patient is not currently on an ACE inhibitor. If switching from an ACE inhibitor, you must allow a 36-hour washout period to avoid the serious risk of angioedema. 1 This is a contraindication, not merely a precaution.
If the patient was previously on low doses of ACE inhibitor or ARB, or is ACE inhibitor/ARB-naïve, consider starting at the reduced dose of 24/26 mg twice daily regardless of renal function, then uptitrate more cautiously. 1
Titration Schedule
After initiating at 49/51 mg twice daily:
- Uptitrate after 2-4 weeks to the target maintenance dose of 97/103 mg twice daily, as tolerated 1
- Monitor blood pressure, potassium, and renal function at each titration step
- The goal is to reach target dose for maximum mortality and morbidity benefit
Evidence Supporting Use in CKD
The 2022 ACC/AHA/HFSA guidelines strongly recommend ARNI replacement of ACE inhibitor/ARB in symptomatic HFrEF (NYHA class II-III) to reduce morbidity and mortality (Class 1, Level B-R). 2 This recommendation applies broadly and is not restricted by renal function in the moderate range.
Recent real-world evidence demonstrates that sacubitril/valsartan is both effective and safe in HFrEF patients with moderate-to-severe CKD:
- A 2024 study showed that 90.77% of patients with moderate-to-severe CKD successfully used lower target doses with significant improvements in NYHA class, ejection fraction, and NT-proBNP, with lower cardiovascular mortality and rehospitalization rates compared to ACE inhibitor/ARB. 3
- Multiple studies confirm modest but acceptable changes in renal function, with mean eGFR declining only 1.8 mL/min/1.73 m² over 24 months while cardiac function improved significantly. 4, 5
- A 2025 meta-analysis found sacubitril/valsartan likely reduced doubling of serum creatinine (RR 0.77) compared to ACE inhibitor/ARB. 6
Monitoring and Safety
Watch for these adverse effects, particularly in CKD patients:
- Hyperkalemia (occurs in ~11% of CKD patients): Monitor potassium at baseline, 1-2 weeks after initiation, and after each dose increase 4
- Symptomatic hypotension (~8%): Check blood pressure before each dose escalation 4
- Worsening renal function (~5%): Monitor eGFR, but expect modest decline is acceptable if cardiac function improves 4, 5
Discontinuation due to adverse effects occurs in only ~7% of CKD patients, indicating good overall tolerability. 5
Clinical Pitfalls to Avoid
- Do not unnecessarily reduce the starting dose based solely on eGFR 45—this is not severe renal impairment
- Do not skip the 36-hour ACE inhibitor washout—angioedema risk is real
- Do not abandon uptitration prematurely—target dose provides maximum benefit, and most CKD patients tolerate it well
- Do not stop therapy for minor eGFR declines—focus on overall clinical improvement in functional status and cardiac parameters rather than isolated creatinine changes
The evidence strongly supports that benefits in mortality, hospitalization, and quality of life outweigh the modest renal function changes in this population. 7, 3, 4, 5